Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian L Harris

Showing results (351-360 of 443) with videos related to

Pageof 45
Sort By:
Oncotarget|August 26, 2014
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancerSiti Norasikin Mohd Nafi, Daniele Generali, Gabriela Kramer-Marek, et al.
Carcinogenesis|July 11, 2012
CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCCSwethajit Biswas, Philip J S Charlesworth, Gareth D H Turner, et al.
Scientific Reports|March 28, 2024
New role of fat-free mass in cancer risk linked with genetic predispositionBenjamin H L Harris, Matteo Di Giovannantonio, Ping Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancerDaniele Generali, Alfredo Berruti, Maria P Brizzi, et al.
Breast Cancer Research and Treatment|September 21, 2005
Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysisSteven Van Laere, Ilse Van der Auwera, Gert G Van den Eynden, et al.
Endocrine-Related Cancer|September 7, 2006
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancerDaniele Generali, Stephen B Fox, Alfredo Berruti, et al.
The American Journal of Pathology|February 20, 2010
Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancerAdrian M Jubb, Elizabeth J Soilleux, Helen Turley, et al.
Molecular Cancer Therapeutics|November 28, 2018
3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism ModifiersDylan T Jones, Alessandro Valli, Syed Haider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancerDaniele Generali, Francesca M Buffa, Alfredo Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patientsDaniele Generali, Gaynor Bates, Alfredo Berruti, et al.
Pageof 45

Showing results (351-360 of 443) with videos related to

Sort By:
Pageof 45
Oncotarget|August 26, 2014
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancerSiti Norasikin Mohd Nafi, Daniele Generali, Gabriela Kramer-Marek, et al.
Carcinogenesis|July 11, 2012
CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCCSwethajit Biswas, Philip J S Charlesworth, Gareth D H Turner, et al.
Scientific Reports|March 28, 2024
New role of fat-free mass in cancer risk linked with genetic predispositionBenjamin H L Harris, Matteo Di Giovannantonio, Ping Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancerDaniele Generali, Alfredo Berruti, Maria P Brizzi, et al.
Breast Cancer Research and Treatment|September 21, 2005
Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysisSteven Van Laere, Ilse Van der Auwera, Gert G Van den Eynden, et al.
Endocrine-Related Cancer|September 7, 2006
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancerDaniele Generali, Stephen B Fox, Alfredo Berruti, et al.
The American Journal of Pathology|February 20, 2010
Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancerAdrian M Jubb, Elizabeth J Soilleux, Helen Turley, et al.
Molecular Cancer Therapeutics|November 28, 2018
3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism ModifiersDylan T Jones, Alessandro Valli, Syed Haider, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancerDaniele Generali, Francesca M Buffa, Alfredo Berruti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patientsDaniele Generali, Gaynor Bates, Alfredo Berruti, et al.
Pageof 45